Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Schenker

P2.13-40 ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)

Journal of Thoracic Oncology

English

Application of a Diabetes Prevention Programme in Immigrant Latino Farm Workers

Occupational and Environmental Medicine

English

Related publications

Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial

Oncotarget

Oncology

2017

English

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

Investigational New Drugs

Oncology

Pharmacology

2014

English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology

English

P3.01-42 Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients With Stages IIIA-IV Nonsquamous NSCLC

Journal of Thoracic Oncology

English

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Journal of Thoracic Oncology

English

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Journal of Clinical Oncology

English

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

English

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology

English

Time-Course Observation of Auditory Brainstem Response in Comatose Patients.

AUDIOLOGY JAPAN

1986

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Schenker

P2.13-40 ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)

Application of a Diabetes Prevention Programme in Immigrant Latino Farm Workers

Related publications

Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

P3.01-42 Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients With Stages IIIA-IV Nonsquamous NSCLC

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Time-Course Observation of Auditory Brainstem Response in Comatose Patients.